Zorevunersen in Children and Adolescents with Dravet Syndrome
The safety profile and initial clinical improvement support the continued development of zorevunersen as a potential disease-modifying treatment for Dravet syndrome. (Supported by Stoke Therapeutics; MONARCH and SWALLOWTAIL ClinicalTrials.gov numbers, NCT04442295 and NCT04740476, respectively; ADMIRAL and LONGWING ISRCTN Registry numbers, ISRCTN99651026 and ISRCTN12811235, respectively.).
Authors
- Pam Ventola
- Andreas Brunklaus (ORCID: https://orcid.org/0000-0002-7728-6903)
- Kelly G. Knupp (ORCID: https://orcid.org/0000-0002-1967-0827)
- Kimberly A. Parkerson
- Barry Ticho
- Archana Desurkar (ORCID: https://orcid.org/0000-0003-4027-5781)
- Linda C. Laux
- M. Scott Perry
- Colin M. Roberts
- Elaine C. Wirrell
- Meena
- John M. Schreiber
- J. Helen Cross
- Fei Wang
- Jessie Lynch
- Joseph Sullivan
- James W. Wheless
Institutions
- Children's National (US)
- Oregon Health & Science University (US)
- National Institute for Health and Care Research (GB)
- Cook Children's Medical Center (US)
- Children's Hospital Colorado (US)
- Connecticut Sea Grant (US)
- Sheffield Children's NHS Foundation Trust (GB)
- Mayo Clinic in Arizona (US)
- Lurie Children's Hospital (US)
- UCSF Benioff Children's Hospital (US)
- Le Bonheur Children's Hospital (US)
- Sheffield Children's Hospital (GB)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- University College London (GB)
- University of Glasgow (GB)
- University of Colorado Denver (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1056/nejmoa2506295
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 66.25
Funders
- Canadian Nuclear Safety Commission